Dexcom’s CEO: FDA’s Nod for G7 Could Come Sometime After ADA

Dexcom winning a nod from FDA for the G7 continuous glucose monitoring system is one of the biggest questions in Diabetes Tech.

During a 1Q22 earnings call, the San Diego, CA-based company’s President, CEO, and chairman, Kevin Sawyer, shed more light on when one of medtech’s most anticipated devices could obtain a nod from FDA.